Antimicrobial‐resistant Helicobacter pylori in Japan: Report of nationwide surveillance for 2018–2020

Establishment of a reference panel of Helicobacter pylori strains for antimicrobial susceptibility testing

(2022) Kenji Yokota et al.   HELICOBACTER

Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report

(2022) Peter Malfertheiner et al.   GUT

Endoscopic screening for gastric cancer in Japan: Current status and future perspectives

(2021) Katsuhiro Mabe et al.   Digestive Endoscopy

Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020

(2021) Hye-Kyung Jung et al.   KOREAN JOURNAL OF INTERNAL MEDICINE

Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition

(2019) Mototsugu Kato et al.   HELICOBACTER

Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori

(2018) Min Li et al.   HELICOBACTER

Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan

(2017) Momoko Tsuda et al.   HELICOBACTER

Impact of health insurance coverage for Helicobacter pylori gastritis on the trends in eradication therapy in Japan: retrospective observational study and simulation study based on real-world data

(2017) Shinzo Hiroi et al.   BMJ Open

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study

(2016) Kazunari Murakami et al.   GUT

Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan

(2013) Kazunari Murakami et al.   JOURNAL OF GASTROENTEROLOGY

Efficacy of Sitafloxacin-Based Rescue Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies

(2011) Juntaro Matsuzaki et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin

(2010) Makoto Sasaki et al.   JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION

Sitafloxacin Activity against Helicobacter pylori Isolates, Including Those with gyrA Mutations

(2009) K. Murakami et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY